NCT05328336View on ClinicalTrials.gov

Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

November 30, 2025

Conditions

Muscle Invasive Bladder Cancer Urothelial Carcinoma

Interventions

DRUG

Tislelizumab Nab paclitaxel

"Drug: Tislelizumab Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles~Other Names:~• BGB-A317 Drug: Nab paclitaxel Nab paclitaxel 200mg will"

Trial Locations (1)

300211

RECRUITING

ianjin Medical University Second Hospital, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Second Hospital

OTHER